Alto Neuroscience, Inc. financial data

Symbol
ANRO on NYSE
Industry
Pharmaceutical Preparations
Location
650 Castro Street, Suite 450, Mountain View, CA
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 27M shares
Common Stock, Shares, Outstanding 27M shares
Weighted Average Number of Shares Outstanding, Basic 26.9M shares +624%
Weighted Average Number of Shares Outstanding, Diluted 26.9M shares +624%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 13.2M USD +86.4%
General and Administrative Expense 5.16M USD +151%
Operating Income (Loss) -18.3M USD -101%
Nonoperating Income (Expense) 2.31M USD +400%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -16M USD -85%
Earnings Per Share, Basic -0.6 USD/shares +74.2%
Earnings Per Share, Diluted -0.6 USD/shares +74.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 193M USD
Other Assets, Current 148K USD
Assets, Current 195M USD
Property, Plant and Equipment, Net 1.44M USD
Assets 197M USD
Accounts Payable, Current 1.84M USD
Employee-related Liabilities, Current 2.5M USD
Accrued Liabilities, Current 5.68M USD
Liabilities, Current 9.84M USD
Liabilities 17.6M USD
Accumulated Other Comprehensive Income (Loss), Net of Tax -89K USD
Retained Earnings (Accumulated Deficit) -106M USD
Stockholders' Equity Attributable to Parent 180M USD
Liabilities and Equity 197M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -11M USD -46%
Net Cash Provided by (Used in) Financing Activities 135M USD +438%
Net Cash Provided by (Used in) Investing Activities -224K USD -967%
Common Stock, Shares Authorized 500M shares
Common Stock, Shares, Issued 27M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 123M USD +607%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 194M USD +228%
Interest Paid, Excluding Capitalized Interest, Operating Activities 248K USD +35.5%
Payments to Acquire Property, Plant, and Equipment 224K USD +967%
Operating Lease, Liability, Current 0 USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares
Additional Paid in Capital 286M USD
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 100K USD 0%
Share-based Payment Arrangement, Expense 1.89M USD +49.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares